在多发性硬化症和其他疾病中使用的sphingosine 1-phosphate受体调节剂
Marisa P McGinley1, Jeffrey A Cohen1
1Mellen Center, Cleveland Clinic, Cleveland, OH, USA.
通过减少循环的淋巴细胞,Sphingosine 1- phosphate (S1P) 受体调节剂已被批准用于多发性硬化症. 进一步的研究支持它们的其他治疗应用潜力.
科学领域:
- 免疫学
- 药理学
- 神经科学
背景情况:
- 斯芬-1- (S1P) 信号通道调节关键的生理过程.
- S1P受体 (S1PRs) 参与淋巴细胞流通,免疫反应和器官功能.
- S1PR被认为是各种疾病的治疗点.
研究的目的:
- 审查S1PR调节器在多发性硬化症中的作用.
- 探索S1PR调节器在多发性硬化症之外的治疗潜力.
主要方法:
- 对S1PR调节器的科学文献的审查.
- 对临床前数据和临床试验结果的分析.
- 对S1PR在多发性硬化症中的作用机制的研究.
主要成果:
- 四种S1PR调节剂 (fingolimod,siponimod,ozanimod,ponesimod) 已被批准用于多发性硬化症.
- 多发性硬化的主要机制涉及S1PR1在淋巴细胞上的内化,减少中枢神经系统的炎症.
- 临床前和临床证据表明它具有更广泛的治疗用途.
结论:
- S1PR调节器代表了多发性硬化症治疗的重大进步.
- S1P信号的多样性表明S1PR调节器在其他疾病中的未来有希望.
- 目前正在进行的研究继续扩大S1PR调节器的治疗领域.
更多相关视频
04:55A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
相关概念视频
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
